Pain prevention drug fails to prove benefit in breast cancer surgery trial

NCT ID NCT03216187

Terminated Prevention Sponsor: Benno Rehberg-Klug Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the drug pregabalin could prevent persistent pain in women at high risk after breast cancer surgery. It included 126 patients who were given either pregabalin or a placebo before and after surgery. The trial was stopped early, and the results did not show a clear benefit in reducing long-term pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERSISTENT POSTOPERATIVE PAIN

Contacts and locations

Locations

Brustzentrum Bern

Bern, Switzerland
Centre Hospitalier Universitaire Vaudois CHUV

Lausanne, 1011, Switzerland
Clinique de Genolier

Genolier, 1272, Switzerland
Clinique des Grangettes

Geneva, Switzerland
Hôpitaux Universitaires de Genève HUG

Geneva, 1211, Switzerland
Inselspital

Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.